Yung Shin Pharmaceutical Ind. Co., Ltd.

Other

The Ohio State University

Taipei Medical University

China Medical University

National Changhua University of Education

Carlsbad Technology, Inc.

Angiorx Corporation

Jih-Hwa Guh

Che-Ming Teng

Shiow-Lin Pan

Sheng-Chu Kuo

Fang-Yu Lee

On Lee

Hui-po Wang

Eric I C Li

Huei-Ting Chen

Ya-Bing Fan

Ya-Lan Chen

Ching-Shih Chen

Li-Jiau Huang

Li-Chen Chou

Chih-Shiang Chang

Fang Yu Lee

Kai-Wei Chang

Wei-Ling Chang

Chun-Li Wang

Jui-Hsien Huang

Jang-Feng Lian

Chi-Meng Hsiao

Ju-Fang Liu

Hui-Po Wang

Yuan-Yi Wang

A compound of formula (I) includes any forms of tautomer or stereoisomer thereof, wherein the formula (I) is presented as: 

Metal complex compound and preparing method and usage thereof

This invention relates to piperazinedione compounds shown in the specification. These compounds are tyrosine kinase inhibitors and can be used to treat cancer.

Piperazinedione compounds

Benzimidazole compounds of formula (I): wherein R, R, R, R, R, X, Y, Z, and Zare defined herein. Also disclosed is a method for treating cancer with benzimidazole compounds.

Benzimidazole compounds and their use as anticancer agents

A method of inhibiting glycolysis in a subject by administering a pharmaceutical composition including a thiazolidinedione derivative to the subject is described. The thiazolidinedione derivatives are effective energy restriction mimetic agents, and can therefore be used to treat or prevent cancer in a subject, treat metabolic disorder, or increase the longevity of a subject. Various thiazolidinedione derivatives are also suitable for activating adenosine phosphate-activated protein kinase or inhibiting IL-6 expression.

Thiazolidinedione energy restriction-mimetic agents

A method for preferentially inhibiting release of pro-inflammatory cytokines over release of anti-inflammatory cytokines using a fused pyrazolyl compound of formula (I): A is R or in which R is H, alkyl, aryl, cyclyl, heteroaryl, or heterocyclyl; each of Ar, Ar, and Ar, independently, is phenyl, thienyl, furyl, or pyrrolyl; each of R, R, R, R, R, and R, independently, is R', nitro, halogen, &#x2014;C(O)&#x2014;OR&#x2032;, &#x2014;C(O)&#x2014;SR&#x2032;, &#x2014;C(O)&#x2014;NR&#x2032;R&#x2033;, &#x2014;(CH)OR&#x2032;, &#x2014;(CH)SR&#x2032;, &#x2014;(CH)NR&#x2032;R&#x2033;, &#x2014;(CH)CN, &#x2014;(CH)C(O)&#x2014;OR&#x2032;, &#x2014;(CH)C(O)H, or Rand Rtogether, Rand Rtogether, or Rand Rtogether are &#x2014;O(CH2)O&#x2014;, in which each of R&#x2032; and R&#x2033;, independently, is H, alkyl, cyclyl, aryl, heteroaryl, heterocyclyl; and m is 0, 1, 2, 3, 4, 5, or 6; and n is 1, 2, or 3. This invention also covers a method of inhibiting activity of NF-&#x3ba;B with such a compound.

Preferential inhibition of release of pro-inflammatory cytokines

A fused pyrazolyl compound of the following formula: wherein A, Ar, Ar, R, R, R, and R, are as defined herein. Also disclosed is a pharmaceutical composition containing an effective amount of the above-described fused pyrazolyl compound.

Fused pyrazolyl compound

This invention relates to a method for treating an angiogenesis-related disease. The method includes administering to a subject in need thereof an effective amount of a piperazinedione compound having the formula: In the above formula, each ofand, independently, is a single bond or a double bond; A is H or CH(RR) whenis a single bond, or C(RR) whenis a double bond; Z is CH(RR) whenis a single bond, or C(RR) whenis a double bond; each of Rand R, independently, is H, C(O)R, C(O)OR, C(O)NRR, or SOR; and each of R, R, R, R, R, and R, independently, is H, C-Calkyl, aryl, heteroaryl, C-Ccycloalkyl, or C-Cheterocycloalkyl; or Rand Rtaken together are C-Ccycloalkyl, C-Cheterocycloalkyl, aryl, or heteroaryl; or Rand Ror Rand Rtaken together are C-Ccycloalkyl, C-Cheterocycloalkyl, aryl, or heteroaryl; provided that one of Rand Ris aryl or heteroaryl.

A method for treating an angiogenesis-related disorder. The method includes administrating to a subject in need thereof an effective amount of a compound of the formula: Each of Ar, Ar, and Ar, independently, is phenyl, thienyl, furyl, pyrrolyl, pyridinyl, or pyrimidinyl; each of R, R, R, R, R, and R, independently, is R, nitro, halogen, C(O)OR, C(O)SR, C(O)NRR', (CH)OR, (CH)SR, (CH)NRR&#x2032;, (CH)CN, (CH)C(O)OR, (CH)CHO, (CH)CH&#x2550;NOR, or Rand Rtogether, Rand Rtogether, or Rand Rtogether are O(CH)O, in which each of R and R&#x2032;, independently, is H or C&#x2dc;Calkyl; and m is 0, 1, 2, 3, 4, 5, or 6, and n is 0, 1, 2, or 3.

Angiogenesis inhibitors

The present invention features a method for treating sepsis. The method includes administrating to a subject in need thereof an effective amount of a fused pyrazolyl compound of formula (I):A is H, C&#x2dc;Calkyl, orin which n is 0, 1, 2, or 3; each of Ar, Ar, and Ar, independently, is phenyl, pyridinyl, thienyl, furyl, or pyrrolyl; and each of R, R, R, R, R, and R, independently, is XYZ; or Rand Rtogether, Rand Rtogether, or Rand Rtogether are O(CH)O; in which X is a bond or C&#x2dc;Calkylene, Y is a bond, O, S, OC(O), OC(O)(CH)C(O)O, C(O)O, C(O)S, C(O)NH, C(O)NC&#x2dc;Calkyl, NH, or NC&#x2dc;Calkyl, and Z is H, halogen, CN, NO, or C&#x2dc;Calkyl; and provided that one of Rand Ris not H.

Methods of treating sepsis

Growing community of inventors

Taipei, Taiwan

Jih-Hwa Guh